RBRoger Hugh Bisby

Roger Hugh Bisby

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Roger Hugh Bisby has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Influence of charge transfer on the isomerisation of stilbene derivatives for application in cancer therapy

    by Nicole Holzmann, Leonardo Bernasconi, Roger H. Bisby, Anthony W. Parker

    The photoisomerisation of non-toxic trans-combretastatin CA4 to its cytotoxic cis isomer demonstrates the high potential of this and similar compounds for localised cancer therapy. The introduction of intramolecular charge-transfer character by altering the substituents of combretastatin systems opens up possibilities to tailor these stilbene derivatives to the special demands of anticancer drugs. In this TDDFT study we explore how absorption wavelengths for both the trans and cis isomers can be red shifted to enable deeper light penetration into tissue and how the trans → cis and cis → trans isomerisations are affected by charge transfer effects to different degrees.


  • Modulation of Antimalarial Activity at a Putative Bisquinoline Receptor In Vivo Using Fluorinated Bisquinolines

    by Alistair J. Fielding, Valentina Lukinović, Philip G. Evans, Said Alizadeh‐Shekalgourabi, Roger H. Bisby, Michael G. B. Drew, Verity Male, Alessio Del Casino, James F. Dunn, Laura E. Randle, et al.

    Antimalarials can interact with heme covalently, by π⋅⋅⋅π interactions or by hydrogen bonding. Consequently, the prototropy of 4‐aminoquinolines and quinoline methanols was investigated by using quantum mechanics. Calculations showed mefloquine protonated preferentially at the piperidine and was impeded at the endocyclic nitrogen because of electronic rather than steric factors. In gas‐phase calculations, 7‐substituted mono‐ and bis‐4‐aminoquinolines were preferentially protonated at the endocyclic quinoline nitrogen. By contrast, compounds with a trifluoromethyl substituent on both the 2‐ and 8‐positions, reversed the order of protonation, which now favored the exocyclic secondary amine nitrogen at the 4‐position. Loss of antimalarial efficacy by CF3groups simultaneously occupying the 2‐ and 8‐positions was recovered if the CF3group occupied the 7‐position. Hence, trifluoromethyl groups buttressing the quinolinyl nitrogen shifted binding of antimalarials to hematin, enabling switching from endocyclic to the exocyclic N. Both theoretical calculations (DFT calculations: B3LYP/BS1) and crystal structure of (±)‐trans‐N1,N2‐bis‐(2,8‐ditrifluoromethylquinolin‐4‐yl)cyclohexane‐1,2‐diamine were used to reveal the preferred mode(s) of interaction with hematin. The order of antimalarial activity in vivo followed the capacity for a redox change of the iron(III) state, which has important implications for the future rational design of 4‐aminoquinoline antimalarials.


  • New Approaches to Photodynamic Therapy from Types I, II and III to Type IV Using One or More Photons

    by Kathrin M. Scherer, Roger H. Bisby, Stanley W. Botchway, Anthony W. Parker

    Photodynamic therapy (PDT) is an alternative cancer treatment to conventional surgery, radiotherapy and chemotherapy. It is based on activating a drug with light that triggers the generation of cytotoxic species that promote tumour cell killing. At present, PDT is mainly used in the treatment of wet age-related macular degeneration, for precancerous conditions of the skin (e.g. actinic keratosis) and in the palliative care of advanced cancers, for instance of the bladder or the oesophagus. PDT is still not used as a first line cancer treatment, which is surprising given the first clinical trials by Dougherty’s group dating back to the 1970’s. PDT has significant advantages over surgery or radiation therapy for low lying tumours due to better cosmetic outcome and localised treatment for the patients. However, despite these advantages and significant developments in optical technology that has enabled light penetration to deeper lying tumours, in excess of 5 cm, a lack of phase III clinical trials has slowed down the uptake of PDT by the healthcare sector as a frontline treatment in cancer. However research continues to demonstrate the potential benefits of PDT and the need to stimulate funding and uptake of clinical studies using next generation photosensitizers offering advanced targeted delivery, improved photodynamic dose combined with modern light delivery technologies. This review surveys the available PDT treatments and emerging novel developments in the field with a particular focus on two-photon techniques that are anticipated to improve the effectiveness of PDT in tissues at depth and on next generation drugs that work without the need of the presence of oxygen for photosensitization making them effective where hypoxia has taken hold.


  • Open Access

    Three-dimensional imaging and uptake of the anticancer drug combretastatin in cell spheroids and photoisomerization in gels with multiphoton excitation

    by Kathrin M. Scherer, Roger H. Bisby, Stanley W. Botchway, John A. Hadfield, John W. Haycock, Anthony W. Parker

    The uptake of E-combretastatins, potential prodrugs of the anticancer Z-isomers, into multicellular spheroids has been imaged by intrinsic fluorescence in three dimensions using two-photon excited fluorescence lifetime imaging with 625-nm ultrafast femtosecond laser pulses. Uptake is initially observed at the spheroid periphery but extends to the spheroid core within 30 min. Using agarose gels as a three-dimensional model, the conversion of Z(trans)→E(cis) via two-photon photoisomerization is demonstrated and the location of this photochemical process may be precisely selected within the micron scale in all three dimensions at depths up to almost 2 mm. We discuss these results for enhanced tissue penetration at longer near-infrared wavelengths for cancer therapy and up to three-photon excitation and imaging using 930-nm laser pulses with suitable combretastatin analogs.


  • A series of flexible design adaptations to the Nikon E‐C1 and E‐C2 confocal microscope systems for UV, multiphoton and FLIM imaging

    by Stanley W. Botchway, Kathrin M. Scherer, Steve Hook, Christopher D. Stubbs, Eleanor Weston, Roger H. Bisby, Anthony W. Parker

    Summary: Multiphoton microscopy is widely employed in the life sciences using extrinsic fluorescence of low‐ and high‐molecular weight labels with excitation and emission spectra in the visible and near infrared regions. For imaging of intrinsic and extrinsic fluorophores with excitation spectra in the ultraviolet region, multiphoton excitation with one‐ or two‐colour lasers avoids the need for ultraviolet‐transmitting excitation optics and has advantages in terms of optical penetration in the sample and reduced phototoxicity. Excitation and detection of ultraviolet emission around 300 nm and below in a typical inverted confocal microscope is more difficult and requires the use of expensive quartz optics including the objective. In this technical note we describe the adaptation of a commercial confocal microscope (Nikon, Japan E‐C1 or E‐C2) for versatile use with Ti‐sapphire and OPO laser sources and the addition of a second detection channel that enables detection of ultraviolet fluorescence and increases detection sensitivity in a typical fluorescence lifetime imaging microscopy experiment. Results from some experiments with this setup illustrate the resulting capabilities.


  • Anticancer phototherapy using activation of E -combretastatins by two-photon–induced isomerization

    by Kathrin M. Scherer, Roger H. Bisby, Stanley W. Botchway, John A. Hadfield, Anthony W. Parker

    The photoisomerization of relatively nontoxic E-combretastatins to clinically active Z-isomers is shown to occur in solution through both one- and two-photon excitations at 340 and 625 nm, respectively. The photoisomerization is also demonstrated to induce mammalian cell death by a two-photon absorption process at 625 nm. Unlike conventional photodynamic therapy (PDT), the mechanism of photoisomerization is oxygen-independent and active in hypoxic environments such as in tumors. The use of red or near-infrared (NIR) light for two-photon excitation allows greater tissue penetration than conventional UV one-photon excitation. The results provide a baseline for the development of a novel phototherapy that overcomes nondiscriminative systemic toxicity of Z-combretastatins and the limitations of PDT drugs that require the presence of oxygen to promote their activity, with the added benefits of two-photon red or NIR excitation for deeper tissue penetration.


  • Open Access

    Ultrafast Vibrational Spectroscopic Studies on the Photoionization of the α-Tocopherol Analogue Trolox C

    by Anthony W. Parker, Roger H. Bisby, Gregory M. Greetham, Philipp Kukura, Kathrin M. Scherer, Michael Towrie

    The initial events after photoexcitation and photoionization of α-tocopherol (vitamin E) and the analogue Trolox C have been studied by femtosecond stimulated Raman spectroscopy, transient absorption spectroscopy and time-resolved infrared spectroscopy. Using these techniques it was possible to follow the formation and decay of the excited state, neutral and radical cation radicals and the hydrated electron that are produced under the various conditions examined. α-Tocopherol and Trolox C in methanol solution appear to undergo efficient homolytic dissociation of the phenolic −OH bond to directly produce the tocopheroxyl radical. In contrast, Trolox C photochemistry in neutral aqueous solutions involves intermediate formation of a radical cation and the hydrated electron which undergo geminate recombination within 100 ps in competition with deprotonation of the radical cation. The results are discussed in relation to recently proposed mechanisms for the reaction of α-tocopherol with peroxyl radicals, which represents the best understood biological activity of this vitamin.


  • Spectroscopy and fluorescence lifetime imaging in live cells of a cyano-substituted combretastatin

    by Kathrin M. Scherer, Roger H. Bisby, Stanley W. Botchway, Greg M. Greetham, John A. Hadfield, Anthony W. Parker, Mike Towrie

    Fluorescence lifetime imaging has been used to observe the real-time uptake in live mammalian cells of a combretastatin-type drug analogue that is a substituted stilbene with a cyano group at the bridging olefinic bond. Fluorescence spectra in a range of solvents show that this molecule has a substantial increase in dipole moment on promotion to the first excited singlet state that is indicative of intramolecular charge transfer (CT) from the methoxy substituents on the aromatic rings to the electron-withdrawing cyano group. This CT process is also demonstrated in picosecond time-resolved infrared measurements. Consistent with these observations, the molecule has been found to have a large two-photon absorption cross-section, and suggests potential routes to the design of a molecule that could be effectively activated by photoisomerisation in a two-photon process.


  • Fluorescence lifetime imaging of E-combretastatin uptake and distribution in live mammalian cells

    by Roger H. Bisby, Stanley W. Botchway, John A. Hadfield, Alan T. McGown, Anthony W. Parker, Kathrin M. Scherer


  • Time-resolved nanosecond fluorescence lifetime imaging and picosecond infrared spectroscopy of combretastatin A-4 in solution and in cellular systems

    by Roger H Bisby, Stanley W Botchway, Greg M Greetham, John A Hadfield, Alan T McGown, Anthony W Parker, Kathrin M Scherer, Mike Towrie